Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1 1

Status

Completed 4Not yet recruiting 2No longer available 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER_GOV 1

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4Gastrointestinal 1Endocrine 1

Conditions

Multiple Myeloma 154Lymphoma 78Lymphoma, Non-Hodgkin 62Neoplasms, Plasma Cell 54Leukemia 52Leukemia, Myeloid, Acute 49Hodgkin Disease 48Precursor Cell Lymphoblastic Leukemia-Lymphoma 45Leukemia, Lymphocytic, Chronic, B-Cell 45Myelodysplastic Syndromes 42Lymphoma, Large B-Cell, Diffuse 41Lymphoma, Follicular 40Lymphoma, Mantle-Cell 38Lymphoma, Large-Cell, Immunoblastic 29Neuroblastoma 27Burkitt Lymphoma 27Lymphoma, B-Cell, Marginal Zone 26Recurrence 22Immunoglobulin Light-chain Amyloidosis 22Myeloproliferative Disorders 18Leukemia, Myeloid, Accelerated Phase 16Hematologic Neoplasms 16Congenital Abnormalities 16Leukemia, Myeloid, Chronic-Phase 14Leukemia, Myelogenous, Chronic, BCR-ABL Positive 14Graft vs Host Disease 14Dendritic Cell Sarcoma, Interdigitating 14Waldenstrom Macroglobulinemia 13Leukemia, Myelomonocytic, Chronic 13Blast Crisis 13

Interventions

Ipilimumab 16incomplete Freund's adjuvant 9Nivolumab 9sargramostim 6Temozolomide 6Dacarbazine 6montanide ISA 51 5MART-1 Antigen 5Blood Specimen Collection 5pembrolizumab 4Ranibizumab 4Melphalan 4Interleukin-2 4Carboplatin 4CTLA-4 Antigen 4Thalidomide 3Surveys and Questionnaires 3MAGEA3 protein, human 3Granulocyte-Macrophage Colony-Stimulating Factor 3AZD 6244 3sotrastaurin 2relatlimab 2gp100 Melanoma Antigen 2fludarabine phosphate 2fludarabine 2entinostat 2aflibercept 2Taxes 2Sunitinib 2Sorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Uveal Melanoma × Melphalan × Clear all
NCT04812470 2025-09-22

HAITILS

Vastra Gotaland Region

Phase 1 Completed
8 enrolled
Dermatologic

Uveal Melanoma, Melanoma

NCT02678572 2023-12-21

FOCUS

Delcath Systems Inc.

Phase 3 Completed
102 enrolled 1 FDA
Dermatologic

Uveal Melanoma

NCT00324727 2021-06-21

Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma

Delcath Systems Inc.

Phase 3 Completed
93 enrolled
Dermatologic

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT00096083 2013-10-23

Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer

Delcath Systems Inc.

Phase 2 Completed
56 enrolled
DermatologicEndocrineGastrointestinal

Adenocarcinoma Of Esophagus, Uveal Melanoma, Appendiceal Neoplasms, Bile Duct Neoplasms, Colonic Neoplasms, Vipoma, Esophageal Neoplasms, Gallbladder Neoplasms, Glucagonoma, Carcinoma, Hepatocellular, Insulinoma, Melanoma, Neoplasms, Pancreatic Neoplasms, Pheochromocytoma, Rectal Neoplasms, Somatostatinoma, Stomach Neoplasms, Carcinoma, Islet Cell, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡